Ireland Cancer Center and Tracon Treat First Patient With Anticancer Drug
Posted on: Tuesday, 26 February 2008, 09:01 CST
The Ireland Cancer Center of University Hospitals Case Medical Center and Tracon Pharmaceuticals have treated the first cancer patient in a Phase I clinical trial with TRC102, a novel anticancer drug.
TRC102 is intended to reverse resistance to Temodar chemotherapy by targeting a specific DNA repair pathway. The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics, as well as preliminary anti-tumor activity, of TRC102 in patients with advanced cancer who are also receiving Temodar. TRC102 is also being developed to reverse resistance to the chemotherapeutic Alimta(r), and a second Phase I trial of TRC102 combined with Alimta(r) is expected to begin later in 2008.
Charles Theuer, president and CEO of Tracon, said: "We view TRC102 as a significant first-in-class therapy that targets an important mechanism of chemotherapy resistance."
Source: Datamonitor
Related Articles
- S BIO Initiates US Phase I Trials of Cancer Drug
- ThromboGenics and BioInvent to Initiate Phase I Trial of Cancer Drug
- SGX Initiates Phase I Trials for Cancer Drug
- Coronado Initiates Phase I Trial of Cancer Drug
- Vion Pharmaceuticals Starts Phase I Trial of Cancer Therapy
- Kinex Begins Phase I Trial for Cancer Drug
- BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
- Tracon Begins Phase I Trial of Cancer Treatment Antibody
- SuperGen Begins Phase I Trial of Cancer Drug
- Cerus Initiates Phase I Trial of Cancer Drug
 |
 |
User Comments (0)
RSS Feeds